Glaxo Consumer Grows 7% Even As JV ‘Moving Parts’ Settle
This article was originally published in The Tan Sheet
An investor suggests divesting its consumer business and other segments to focus on its Rx and vaccines operations, but CEO Witty says the consumer JV’s early returns point to long-term success. “We see very significant opportunity to create value through the expansion of the margin in consumer,” he says.
Register for our free email digests: